Create New Account    |   
 
Branch Locator   |   
 
Home | About Us | Careers | Sitemap | Contact Us | Downloads
Product & Services
  | 
Markets
  | 
Derivatives
  | 
Commodities
  | 
BLOG
  | 
Knowledge Center
  | 
Business Associates
 
Outcome of RBI monetary policy to dictate market trend
05-Dec-18   08:24 Hrs IST

Trading of Nifty 50 index futures on the Singapore stock exchange indicates that the Nifty could rise 11 points at the opening bell.

The outcome of the Reserve Bank of India's (RBI) monetary policy meeting will be closely watched. The Monetary Policy Committee (MPC) will conclude its two-day meet today, 5 December 2018. The resolution of the MPC will be announced on 5 December 2018.

Overseas, Asian equities were trading mixed. US stocks plunged on Tuesday, with the Dow Jones Industrial Average tumbling almost 800 points, as a litany of concerns wiped out the rally in risk assets.

Back home, key equities indices snapped six-day rising streak to end with modest losses yesterday, 4 December 2018 due to profit selling. The Sensex fell 106.69 points or 0.29% to settle at 36,134.31.

The trading activity on that day showed that the foreign portfolio investors (FPIs) sold shares worth a net Rs 55.89 crore yesterday, 4 December 2018, as per provisional data released by the stock exchanges. Domestic institutional investors (DIIs) sold shares worth a net Rs 521.38 crore yesterday, 4 December 2018, as per provisional data.

Among corporate news, Tata Motors announced that S&P Global Ratings has lowered the credit rating of the company and luxury car unit, Jaguar Land Rover Automotive Plc (JLR), citing weaker profitability at JLR. S&P cut its rating on Tata Motors' issuer credit and senior unsecured notes to 'BB-' from 'BB'. The ratings remain on negative watch. The announcement was made after market hours yesterday, 4 December 2018.

Lupin announced the launch of Silodosin Capsules 4mg and 8mg, having received an approval from the United States Food and Drug Administration (USFDA) earlier. Lupin's Silodosin Capsules 4mg and 8mg; is the generic equivalent of Allergan's Rapaflo. An alpha-1 adrenergic receptor antagonist, it is indicated for the treatment of the signs and symptoms of benign prostatic hyperplasia (BPH). Rapaflo had annual sales of $198.5 million in the US (IQVIA MAT September 2018). The announcement was made after market hours yesterday, 4 December 2018.

Powered by Capital Market - Live News

BSE | NSE
Friday, February 22, 2019    
Asian Paints    1398.30  (0.55)    |    
Axis Bank    703.05  (6.15)    |    
Bajaj Auto    2816.70  (7.05)    |    
Bajaj Fin.    2641.05  (-12.00)    |    
Bharti Airtel    313.00  (2.80)    |    
Coal India    215.25  (1.55)    |    
H D F C    1885.05  (-6.55)    |    
HCL Technologi...    1063.15  (9.65)    |    
HDFC Bank    2091.65  (-23.50)    |    
Hero Motocorp    2687.35  (43.65)    |    
Hind. Unilever    1767.80  (14.20)    |    
ICICI Bank    351.75  (1.35)    |    
IndusInd Bank    1463.35  (-8.20)    |    
Infosys    733.35  (0.00)    |    
ITC    274.30  (-0.60)    |    
Kotak Mah. Ban...    1241.05  (-47.85)    |    
Larsen & Toubr...    1279.45  (-2.80)    |    
M & M    646.10  (12.75)    |    
Maruti Suzuki    6916.40  (119.60)    |    
NTPC    139.70  (3.10)    |    
O N G C    148.55  (1.55)    |    
Power Grid Cor...    181.90  (0.15)    |    
Reliance Inds.    1232.60  (-13.85)    |    
St Bk of India    270.75  (3.20)    |    
Sun Pharma.Ind...    430.40  (0.65)    |    
Tata Motors    174.55  (4.85)    |    
Tata Motors-DV...    89.20  (1.20)    |    
Tata Steel    501.95  (4.05)    |    
TCS    1925.90  (13.65)    |    
Vedanta    169.30  (4.70)    |    
Yes Bank    221.95  (6.95)    |